HRP20191074T1 - Polimeri koji vežu protone za oralnu primjenu - Google Patents
Polimeri koji vežu protone za oralnu primjenu Download PDFInfo
- Publication number
- HRP20191074T1 HRP20191074T1 HRP20191074TT HRP20191074T HRP20191074T1 HR P20191074 T1 HRP20191074 T1 HR P20191074T1 HR P20191074T T HRP20191074T T HR P20191074TT HR P20191074 T HRP20191074 T HR P20191074T HR P20191074 T1 HRP20191074 T1 HR P20191074T1
- Authority
- HR
- Croatia
- Prior art keywords
- cross
- amine
- bis
- linked
- pharmaceutical composition
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims 17
- 150000001412 amines Chemical class 0.000 claims 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 12
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 238000006116 polymerization reaction Methods 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 239000000872 buffer Substances 0.000 claims 5
- 239000003431 cross linking reagent Substances 0.000 claims 5
- 239000000178 monomer Substances 0.000 claims 5
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 claims 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 4
- 239000012530 fluid Substances 0.000 claims 4
- 230000002496 gastric effect Effects 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- YHRUOJUYPBUZOS-UHFFFAOYSA-N 1,3-dichloropropane Chemical compound ClCCCCl YHRUOJUYPBUZOS-UHFFFAOYSA-N 0.000 claims 3
- 239000008367 deionised water Substances 0.000 claims 3
- 229910021641 deionized water Inorganic materials 0.000 claims 3
- 230000008961 swelling Effects 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 2
- VOUJQKYOLXSFCM-UHFFFAOYSA-N 3-chloro-n-(3-chloropropyl)propan-1-amine Chemical compound ClCCCNCCCCl VOUJQKYOLXSFCM-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- OTBHHUPVCYLGQO-UHFFFAOYSA-N bis(3-aminopropyl)amine Chemical compound NCCCNCCCN OTBHHUPVCYLGQO-UHFFFAOYSA-N 0.000 claims 2
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims 2
- GAXGZXPYWABFNX-UHFFFAOYSA-N n,n'-bis(3-chloropropyl)ethane-1,2-diamine Chemical compound ClCCCNCCNCCCCl GAXGZXPYWABFNX-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 238000010526 radical polymerization reaction Methods 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims 1
- OPCJOXGBLDJWRM-UHFFFAOYSA-N 1,2-diamino-2-methylpropane Chemical compound CC(C)(N)CN OPCJOXGBLDJWRM-UHFFFAOYSA-N 0.000 claims 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 claims 1
- UYBWIEGTWASWSR-UHFFFAOYSA-N 1,3-diaminopropan-2-ol Chemical compound NCC(O)CN UYBWIEGTWASWSR-UHFFFAOYSA-N 0.000 claims 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 claims 1
- RVJABZUDCPZPPM-UHFFFAOYSA-N 1,4,7,10,13,16-hexazacyclooctadecane Chemical compound C1CNCCNCCNCCNCCNCCN1 RVJABZUDCPZPPM-UHFFFAOYSA-N 0.000 claims 1
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 claims 1
- ITWBWJFEJCHKSN-UHFFFAOYSA-N 1,4,7-triazonane Chemical compound C1CNCCNCCN1 ITWBWJFEJCHKSN-UHFFFAOYSA-N 0.000 claims 1
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 claims 1
- KUFDRRWNPNXBRF-UHFFFAOYSA-N 1,4,8,12-tetrazacyclopentadecane Chemical compound C1CNCCCNCCNCCCNC1 KUFDRRWNPNXBRF-UHFFFAOYSA-N 0.000 claims 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims 1
- PWGJDPKCLMLPJW-UHFFFAOYSA-N 1,8-diaminooctane Chemical compound NCCCCCCCCN PWGJDPKCLMLPJW-UHFFFAOYSA-N 0.000 claims 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims 1
- DDHUNHGZUHZNKB-UHFFFAOYSA-N 2,2-dimethylpropane-1,3-diamine Chemical compound NCC(C)(C)CN DDHUNHGZUHZNKB-UHFFFAOYSA-N 0.000 claims 1
- UWMHHZFHBCYGCV-UHFFFAOYSA-N 2,3,2-tetramine Chemical compound NCCNCCCNCCN UWMHHZFHBCYGCV-UHFFFAOYSA-N 0.000 claims 1
- GFIWSSUBVYLTRF-UHFFFAOYSA-N 2-[2-(2-hydroxyethylamino)ethylamino]ethanol Chemical compound OCCNCCNCCO GFIWSSUBVYLTRF-UHFFFAOYSA-N 0.000 claims 1
- FDAYLTPAFBGXAB-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)ethanamine Chemical compound ClCCN(CCCl)CCCl FDAYLTPAFBGXAB-UHFFFAOYSA-N 0.000 claims 1
- KDRUIMNNZBMLJR-UHFFFAOYSA-N 2-isopropylaminoethylamine Chemical compound CC(C)NCCN KDRUIMNNZBMLJR-UHFFFAOYSA-N 0.000 claims 1
- JZUHIOJYCPIVLQ-UHFFFAOYSA-N 2-methylpentane-1,5-diamine Chemical compound NCC(C)CCCN JZUHIOJYCPIVLQ-UHFFFAOYSA-N 0.000 claims 1
- JOMNTHCQHJPVAZ-UHFFFAOYSA-N 2-methylpiperazine Chemical compound CC1CNCCN1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 claims 1
- BDXGMDGYOIWKIF-UHFFFAOYSA-N 2-methylpropane-1,3-diamine Chemical compound NCC(C)CN BDXGMDGYOIWKIF-UHFFFAOYSA-N 0.000 claims 1
- RXFCIXRFAJRBSG-UHFFFAOYSA-N 3,2,3-tetramine Chemical compound NCCCNCCNCCCN RXFCIXRFAJRBSG-UHFFFAOYSA-N 0.000 claims 1
- KTLIZDDPOZZHCD-UHFFFAOYSA-N 3-(2-aminoethylamino)propan-1-ol Chemical compound NCCNCCCO KTLIZDDPOZZHCD-UHFFFAOYSA-N 0.000 claims 1
- -1 3-(methylamino)pyrrolidino Chemical group 0.000 claims 1
- PQIYSSSTRHVOBW-UHFFFAOYSA-N 3-bromopropan-1-amine;hydron;bromide Chemical compound Br.NCCCBr PQIYSSSTRHVOBW-UHFFFAOYSA-N 0.000 claims 1
- 208000010444 Acidosis Diseases 0.000 claims 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 claims 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
- 206010027417 Metabolic acidosis Diseases 0.000 claims 1
- CJKRXEBLWJVYJD-UHFFFAOYSA-N N,N'-diethylethylenediamine Chemical compound CCNCCNCC CJKRXEBLWJVYJD-UHFFFAOYSA-N 0.000 claims 1
- 125000002723 alicyclic group Chemical group 0.000 claims 1
- 125000000746 allylic group Chemical group 0.000 claims 1
- LHIJANUOQQMGNT-UHFFFAOYSA-N aminoethylethanolamine Chemical compound NCCNCCO LHIJANUOQQMGNT-UHFFFAOYSA-N 0.000 claims 1
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 claims 1
- 239000012062 aqueous buffer Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 150000001555 benzenes Chemical class 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- TXFLGZOGNOOEFZ-UHFFFAOYSA-N bis(2-chloroethyl)amine Chemical compound ClCCNCCCl TXFLGZOGNOOEFZ-UHFFFAOYSA-N 0.000 claims 1
- MRNZSTMRDWRNNR-UHFFFAOYSA-N bis(hexamethylene)triamine Chemical compound NCCCCCCNCCCCCCN MRNZSTMRDWRNNR-UHFFFAOYSA-N 0.000 claims 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- YQLZOAVZWJBZSY-UHFFFAOYSA-N decane-1,10-diamine Chemical compound NCCCCCCCCCCN YQLZOAVZWJBZSY-UHFFFAOYSA-N 0.000 claims 1
- 150000004985 diamines Chemical class 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- PWSKHLMYTZNYKO-UHFFFAOYSA-N heptane-1,7-diamine Chemical compound NCCCCCCCN PWSKHLMYTZNYKO-UHFFFAOYSA-N 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 claims 1
- 229920001519 homopolymer Polymers 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- HKAXXLXZPQLQHR-UHFFFAOYSA-N n',2-dimethylpropane-1,3-diamine Chemical compound CNCC(C)CN HKAXXLXZPQLQHR-UHFFFAOYSA-N 0.000 claims 1
- QMXSDTGNCZVWTB-UHFFFAOYSA-N n',n'-bis(3-aminopropyl)propane-1,3-diamine Chemical compound NCCCN(CCCN)CCCN QMXSDTGNCZVWTB-UHFFFAOYSA-N 0.000 claims 1
- HYSQEYLBJYFNMH-UHFFFAOYSA-N n'-(2-aminoethyl)-n'-methylethane-1,2-diamine Chemical compound NCCN(C)CCN HYSQEYLBJYFNMH-UHFFFAOYSA-N 0.000 claims 1
- OTDKXAKMLKPMDA-UHFFFAOYSA-N n'-(3-aminopropyl)-n'-[2-[bis[2-[bis(3-aminopropyl)amino]ethyl]amino]ethyl]propane-1,3-diamine Chemical compound NCCCN(CCCN)CCN(CCN(CCCN)CCCN)CCN(CCCN)CCCN OTDKXAKMLKPMDA-UHFFFAOYSA-N 0.000 claims 1
- KMBPCQSCMCEPMU-UHFFFAOYSA-N n'-(3-aminopropyl)-n'-methylpropane-1,3-diamine Chemical compound NCCCN(C)CCCN KMBPCQSCMCEPMU-UHFFFAOYSA-N 0.000 claims 1
- DFPGBRPWDZFIPP-UHFFFAOYSA-N n'-butylethane-1,2-diamine Chemical compound CCCCNCCN DFPGBRPWDZFIPP-UHFFFAOYSA-N 0.000 claims 1
- SCZVXVGZMZRGRU-UHFFFAOYSA-N n'-ethylethane-1,2-diamine Chemical compound CCNCCN SCZVXVGZMZRGRU-UHFFFAOYSA-N 0.000 claims 1
- KFIGICHILYTCJF-UHFFFAOYSA-N n'-methylethane-1,2-diamine Chemical compound CNCCN KFIGICHILYTCJF-UHFFFAOYSA-N 0.000 claims 1
- QHJABUZHRJTCAR-UHFFFAOYSA-N n'-methylpropane-1,3-diamine Chemical compound CNCCCN QHJABUZHRJTCAR-UHFFFAOYSA-N 0.000 claims 1
- KFDIDIIKNMZLRZ-UHFFFAOYSA-N n'-propan-2-ylpropane-1,3-diamine Chemical compound CC(C)NCCCN KFDIDIIKNMZLRZ-UHFFFAOYSA-N 0.000 claims 1
- MFIGJRRHGZYPDD-UHFFFAOYSA-N n,n'-di(propan-2-yl)ethane-1,2-diamine Chemical compound CC(C)NCCNC(C)C MFIGJRRHGZYPDD-UHFFFAOYSA-N 0.000 claims 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 claims 1
- KGHYGBGIWLNFAV-UHFFFAOYSA-N n,n'-ditert-butylethane-1,2-diamine Chemical compound CC(C)(C)NCCNC(C)(C)C KGHYGBGIWLNFAV-UHFFFAOYSA-N 0.000 claims 1
- ZKEGVCJAZHCGTG-UHFFFAOYSA-N n,n,n',n'-tetrakis(2-aminoethyl)propane-1,3-diamine Chemical group NCCN(CCN)CCCN(CCN)CCN ZKEGVCJAZHCGTG-UHFFFAOYSA-N 0.000 claims 1
- LYBWJVKFJAIODE-UHFFFAOYSA-N n,n,n',n'-tetrakis(3-aminopropyl)butane-1,4-diamine Chemical compound NCCCN(CCCN)CCCCN(CCCN)CCCN LYBWJVKFJAIODE-UHFFFAOYSA-N 0.000 claims 1
- UQUPIHHYKUEXQD-UHFFFAOYSA-N n,n′-dimethyl-1,3-propanediamine Chemical compound CNCCCNC UQUPIHHYKUEXQD-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- WTSXICLFTPPDTL-UHFFFAOYSA-N pentane-1,3-diamine Chemical compound CCC(N)CCN WTSXICLFTPPDTL-UHFFFAOYSA-N 0.000 claims 1
- 229940085991 phosphate ion Drugs 0.000 claims 1
- RHPBLLCTOLJFPH-UHFFFAOYSA-N piperidin-2-ylmethanamine Chemical compound NCC1CCCCN1 RHPBLLCTOLJFPH-UHFFFAOYSA-N 0.000 claims 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 claims 1
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 claims 1
- 210000000689 upper leg Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/024—Polyamines containing oxygen in the form of ether bonds in the main chain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
- G01N2001/4083—Concentrating samples by other techniques involving separation of suspended solids sedimentation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
- G01N2001/4088—Concentrating samples by other techniques involving separation of suspended solids filtration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Claims (22)
1. Farmaceutski pripravak koji sadrži umreženi aminski polimer koji veže protone i sadrži ostatak amina koji odgovara Formuli 2:
pri čemu je navedeni umreženi aminski polimer umrežen sa umrežavajućim agensom koji može biti upotrijebljen u reakcijama supstitucijske polimerizacije i reakcijama umrežavanja nakon polimerizacije, gdje je agens za umrežavanje jedan ili više od agensa iz skupine koju čine: dihaloalkan, di(haloalkil)amin, tri(haloalkil)amin, bis(halometil)benzeni, tri(halometil)benzen, tetra(halometil)benzen, 1,2-dibromoetan, 1,3-dikloropropan, 1,2-dikloroetan, 1-bromo-2-kloroetan, 1,3-dibromopropan, bis(2-kloroetil)amin, tris(2-kloroetil)amin, bis(2-kloroetil)metilamin, bis(halometil)benzen, bis(halometil)bifenil, bis(halometil)naftalen, 1,2-bis(3-kloropropilamino)etan, bis(3-kloropropil)amin ili 1,3-dikloropropan i gdje
m i n su nezavisno cijeli brojevi koji nisu negativni;
R10, R20, R30 i R40 su nezavisno vodik, hidrokarbil ili supstituirani hidrokarbil;
X1 je
X2 je hidrokarbil ili supstituirani hidrokarbil;
svaki X11 je nezavisno vodik, hidrokarbil, supstituirani hidrokarbil, hidroksi ili amino; i
z je broj koji nije negativan,
umreženi aminski polimer je sa (i) ravnotežnim kapacitetom vezanja protona od najmanje 5 mmol/g i kapacitetom vezanja kloridnih iona od najmanje 5 mmol/g, u vodenom puferu simulirane želučane tekućine ("SGF") koji sadrži 35 mM NaCl i 63 mM HCl, pri pH 1,2 i na 37°C, (ii) ravnotežnim odnosom bubrenja u deioniziranoj vodi od oko 2 ili manje i (iii) molarnim odnosom vezanja kloridnih iona i fosfatnih iona od najmanje 1:1, tim redom, u vodenom simuliranom anorganskom puferu tankog crijeva ("SIB") koji sadrži 36 mM NaCl, 20 mM NaH2PO4 i 50 mM 2-(N-morfolino)etansulfonske kiseline (MES) i podešen je do pH 5,5, na 37°C.
2. Farmaceutski pripravak prema patentnom zahtjevu 1, gdje je umreženi aminski polimer umrežen s dihaloalkanom.
3. Farmaceutski pripravak prema patentnom zahtjevu 1 ili 2, gdje dihaloalkan sadrži dva ista atoma halogena ili kombinaciju dva različita atoma halogena.
4. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-3, gdje je umreženi aminski polimer sa ravnotežnim kapacitetom vezanja klorida od najmanje 7,5 mmol/g u vodenom puferu simulirane želučane tekućine ("SGF") koji sadrži 35 mM NaCl i 63 mM HCl, pH 1,2 i na 37°C.
5. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-3, gdje je umreženi aminski polimer sa ravnotežnim kapacitetom vezanja klorida od najmanje 10 mmol/g u vodenom puferu simulirane želučane tekućine ("SGF") koji sadrži 35 mM NaCl i 63 mM HCl, pri pH 1,2 i na 37°C.
6. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-5, gdje je X2 alifatičan ili heteroalifatičan.
7. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-6, gdje je m 1-3 i X11 je vodik, alifatičan ili heteroalifatičan.
8. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-5, gdje umreženi aminski polimer sadrži ostatak amina koji odgovara Formuli 2b:
gdje
m i n su nezavisno cijeli brojevi koji nisu negativni;
svaki R12 je nezavisno vodik, supstituirani hidrokarbil ili hidrokarbil;
R22 i R32 su nezavisno vodik supstituiran hidrokarbil ili hidrokarbil;
R42 je vodik, hidrokarbil ili supstituirani hidrokarbil;
X1 je
X2 je alkil, aminoalkil ili alkanol;
svaki X13 je nezavisno vodik, hidroksi, alicikličan, amino, aminoalkil, halogen, alkil, heteroaril, boronska kiselina ili aril;
z je broj koji nije negativan; i
amin koji odgovara Formuli 2b sadrži najmanje jednu alilnu skupinu.
9. Farmaceutski pripravak prema patentnom zahtjevu 8, gdje su m i z nezavisno 0-3 i n je 0 ili 1.
10. Farmaceutski pripravak prema patentnom zahtjevu 8 ili 9, gdje (i) m je pozitivan cijeli broj i R12, R22 i R42, u kombinaciji, sadrže najmanje dva alilna ili vinilna ostatka ili (ii) n je pozitivan cijeli broj i R12, R32 i R42, u kombinaciji, sadrže najmanje dva alilna ili vinilna ostatka.
11. Farmaceutski pripravak prema patentnom zahtjevu 8 ili 9, gdje je umreženi aminski polimer umrežen sa umrežavajućim agensom izabranim iz skupine koju čine: bis(3-kloropropil)amin, 1,3-dikkloropropan i 1,2-bis(3-kloropropilamino)etan.
12. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-5, gdje je umreženi aminski polimer pripremlјen (i) supstitucijskom polimerizacijom polifunkcionalnih reagensa od kojih najmanje jedan sadrži aminske ostatke, (2) radikalskom polimerizacijom monomera koji sadrže najmanje jedan aminski ostatak ili ostatak koji sadrži dušik ili (3) umrežavanjem intermedijera koji sadrži amin s agensom za umrežavanje koji opcionalno sadrži aminske ostatke.
13. Farmaceutski pripravak prema patentnom zahtjevu 12, gdje je umreženi aminski polimer umreženi homopolimer ili umreženi kopolimer.
14. Farmaceutski pripravak prema patentnom zahtjevu 12, gdje je umreženi aminski polimer pripremlјen polimerizacijom monomera koji sadrže amin s agensom za umrežavanje, u reakciji supstitucijske polimerizacije.
15. Farmaceutski pripravak prema patentnom zahtjevu 14, gdje je monomer koji sadrži amin linearni amin koji posjeduje najmanje dva reaktivna aminska ostatka koji sudjeluju u reakciji supstitucijske polimerizacije.
16. Farmaceutski pripravak prema patentnom zahtjevu 14 ili 15, gdje je monomer koji sadrži amin 1,3-bis[bis(2-aminoetil)amino]propan, 3-amino-1-{[2-(bis{2-[bis(3-aminopropil)amino]etil}amino)etil](3-aminopropil)amino}propan, 2-[bis(2-aminoetil)amino]etanamin, tris(3-aminopropil)amin, 1,4-bis[bis(3-aminopropil)amino]butan, 1,2-etandiamin, 2-amino-1-(2-aminoetilamino)etan, 1,2-bis(2-aminoetilamino)etan, 1,3-propandiamin, 3,3'-diaminodipropilamin 2,2-dimetil-1,3-propandiamin, 2-metil-1,3-propandiamin, N,N’-dimetil-1,3-propandiamin, N-metil-1,3-diaminopropan, 3,3’-diamino-N-metildipropilamin, 1,3-diaminopentan, 1,2-diamino-2-metilpropan, 2-metil-1,5-diaminopentan, 1,2-diaminopropan, 1,10-diaminodekan, 1,8-diaminooktan, 1,9-diaminooktan, 1,7-diaminoheptan, 1,6-diaminoheksan, 1,5-diaminopentan, 3-bromopropilamin hidrobromid, N,2-dimetil-1,3-propandiamin, N-izopropil-1,3-diaminopropan, N,N’-bis(2-aminoetil)-1,3-propandiamin, N,N’-bis(3-aminopropil)etilendiamin, N,N’-bis(3-aminopropil)-1,4-butandiamin tetrahidroklorid, 1,3-diamino-2-propanol, N-etiletilendiamin, 2,2'-diamino-N-metildietilamin, N,N’-dietiletilendiamin, N-izopropiletilendiamin, N-metiletilendiamin, N,N’-di-terc-butiletilendiamin, N,N’-diizopropiletilendiamin, N,N’-dimetiletilendiamin, N-butiletilendiamin, 2-(2-aminoetilamino)etanol, 1,4,7,10,13,16-heksaazacikloktadekan, 1,4,7,10-tetraazaciklododekan, 1,4,7-triazaciklononan, N,N’-bis(2-hidroksietil)etilendiamin, piperazin, bis(heksametilen)triamin, N-(3-hidroksipropil)etilendiamin, N-(2-aminoetil)piperazin, 2-metilpiperazin, homopiperazin, 1,4,8,11-tetraazaciklotetradekan, 1,4,8,12-tetraazaciklopentadekan, 2-(aminometil)piperidin ili 3-(metilamino)pirolidino.
17. Farmaceutski pripravak prema patentnom zahtjevu 12, pri čemu priprema umreženog aminskog polimera obuhvaća radikalsku polimerizaciju aminskog monomera koji sadrži najmanje jedan aminski ostatak ili ostatak koji sadrži dušik.
18. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, gdje je umreženi aminski polimer sa ravnotežnim odnosom bubrenja u deioniziranoj vodi od oko 1,5 ili manje.
19. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, gdje je umreženi aminski polimer sa ravnotežnim odnosom bubrenja u deioniziranoj vodi od oko 1 ili manje.
20. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, gdje je umreženi aminski polimer sa molarnim odnosom vezanja kloridnih iona i fosfatnih iona od najmanje 2:1, tim redom, u vodenom simuliranom anorganskom puferu tankog crijeva ("SIB") koji sadrži 36 mM NaCl, 20 mM NaH2PO4 i 50 mM 2-(N-morfolino)etansulfonske kiseline (MES) i podešen je do pH 5,5, na 37°C.
21. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, gdje je umreženi aminski polimer sa kapacitetom vezanja protona od najmanje 10 mmol/g i kapacitetom vezanja kloridnih iona od najmanje 10 mmol/g, u vodenom puferu simulirane želučane tekućine ("SGF") koji sadrži 35 mM NaCl i 63 mM HCl, pri pH 1,2 i na 37°C.
22. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, za upotrebu u postupku liječenja metaboličke acidoze putem oralne primjene navedene farmaceutske mješavine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361831445P | 2013-06-05 | 2013-06-05 | |
| EP17177221.3A EP3287133B1 (en) | 2013-06-05 | 2014-06-05 | Proton-binding polymers for oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191074T1 true HRP20191074T1 (hr) | 2019-09-20 |
Family
ID=51212941
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171590TT HRP20171590T1 (hr) | 2013-06-05 | 2017-10-18 | Polimeri koji vežu protone za oralnu primjenu |
| HRP20191074TT HRP20191074T1 (hr) | 2013-06-05 | 2019-06-14 | Polimeri koji vežu protone za oralnu primjenu |
| HRP20201767TT HRP20201767T1 (hr) | 2013-06-05 | 2020-11-02 | Polimeri koji vežu protone za oralnu primjenu |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171590TT HRP20171590T1 (hr) | 2013-06-05 | 2017-10-18 | Polimeri koji vežu protone za oralnu primjenu |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201767TT HRP20201767T1 (hr) | 2013-06-05 | 2020-11-02 | Polimeri koji vežu protone za oralnu primjenu |
Country Status (25)
| Country | Link |
|---|---|
| US (8) | US9205107B2 (hr) |
| EP (4) | EP3003327B1 (hr) |
| JP (4) | JP6453860B2 (hr) |
| KR (4) | KR20210131457A (hr) |
| CN (3) | CN105377270B (hr) |
| AU (3) | AU2014274817B2 (hr) |
| BR (1) | BR112015030142B1 (hr) |
| CA (1) | CA2912911C (hr) |
| CY (3) | CY1119611T1 (hr) |
| DK (3) | DK3287133T3 (hr) |
| ES (3) | ES2646271T3 (hr) |
| HK (3) | HK1222120A1 (hr) |
| HR (3) | HRP20171590T1 (hr) |
| HU (3) | HUE034836T2 (hr) |
| IL (3) | IL242758B (hr) |
| LT (3) | LT3578185T (hr) |
| MX (3) | MX364785B (hr) |
| NO (1) | NO2905572T3 (hr) |
| PL (2) | PL3003327T3 (hr) |
| PT (3) | PT3287133T (hr) |
| RS (2) | RS61005B1 (hr) |
| RU (1) | RU2728778C2 (hr) |
| SI (3) | SI3578185T1 (hr) |
| TR (1) | TR201909355T4 (hr) |
| WO (1) | WO2014197725A1 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014197725A1 (en) | 2013-06-05 | 2014-12-11 | Tricida, Inc. | Proton-binding polymers for oral administration |
| MA41150B1 (fr) * | 2014-12-10 | 2020-06-30 | Tricida Inc | Polymères de liaison aux protons pour administration orale |
| MA44875A (fr) * | 2016-05-06 | 2019-03-13 | Tricida Inc | Compositions pour le traitement de troubles acido-basiques |
| BR112019013364A2 (pt) | 2016-12-28 | 2020-04-14 | Fujifilm Corp | emulsão de polímero contendo átomo de nitrogênio ou sal do mesmo, método de produção para o mesmo e método de produção para partículas |
| US10934380B1 (en) | 2017-09-25 | 2021-03-02 | Tricida, Inc. | Crosslinked poly(allylamine) polymer pharmaceutical compositions |
| JP6992084B2 (ja) | 2017-10-16 | 2022-01-13 | 富士フイルム株式会社 | 高リン血症治療剤 |
| AU2018360867A1 (en) * | 2017-11-03 | 2020-04-30 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
| WO2019090177A1 (en) * | 2017-11-03 | 2019-05-09 | Tricida, Inc. | Method of treating acid-base disorders |
| MA51628A (fr) * | 2018-06-04 | 2021-03-17 | Tricida Inc | Méthode de traitement de troubles de l'équilibre acido-basique |
| WO2021016100A1 (en) * | 2019-07-19 | 2021-01-28 | ACatechol, Inc. | Molecularly well-defined antibiofouling and polyionic coatings |
| EP4053179A1 (en) | 2021-03-01 | 2022-09-07 | Tricida Inc. | Crosslinked poly(allylamine) polymer pharmaceutical compositions |
| WO2023109825A1 (zh) * | 2021-12-14 | 2023-06-22 | 上海石趣医药科技有限公司 | 氧化银和/或其水合物在制备药物中的用途 |
| CN115260355A (zh) * | 2022-05-16 | 2022-11-01 | 江苏中天药业有限公司 | 一种阴离子交换树脂、其制备方法、该树脂与药物的复合物和其掩味制剂 |
| KR20230047972A (ko) | 2023-03-21 | 2023-04-10 | 최문수 | 개인별 맞춤형 그립 형상이 형성된 운동기구용 손잡이 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| US6444221B1 (en) | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
| US5534259A (en) * | 1993-07-08 | 1996-07-09 | Liposome Technology, Inc. | Polymer compound and coated particle composition |
| US5496545A (en) | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| US5648355A (en) | 1994-02-09 | 1997-07-15 | Kos Pharmaceutical, Inc. | Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin |
| TW474813B (en) | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
| EP0786993B1 (en) | 1994-10-17 | 2002-06-05 | Peter W. Stacpoole | Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and their use in the treatment of metabolic and cardiovascular disorders |
| US20020006899A1 (en) | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
| US5753706A (en) | 1996-12-16 | 1998-05-19 | Hsu; Chen Hsing | Methods for treating renal failure |
| AUPO758297A0 (en) | 1997-06-27 | 1997-07-24 | Rowe, James Baber | Control of acidic gut syndrome |
| US6726905B1 (en) | 1997-11-05 | 2004-04-27 | Genzyme Corporation | Poly (diallylamines)-based phosphate binders |
| WO1999040990A1 (en) | 1998-02-17 | 1999-08-19 | University Of Maryland | Anion binding polymers and the use thereof |
| US6485703B1 (en) | 1998-07-31 | 2002-11-26 | The Texas A&M University System | Compositions and methods for analyte detection |
| US6271264B1 (en) | 1998-12-01 | 2001-08-07 | Geltex Pharmaceuticals, Inc. | Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants |
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| GB9927088D0 (en) | 1999-11-17 | 2000-01-12 | Secr Defence | Use of poly(diallylamine) polymers |
| US6844372B2 (en) | 2000-03-09 | 2005-01-18 | Hisamitsu Pharmaceutical Co., Inc. | Crosslinked anion-exchange resin or salt thereof and phosphorus adsorbent comprising the same |
| US20040059065A1 (en) | 2000-03-09 | 2004-03-25 | Takeshi Goto | Crosslinked anion-exchange resin or salt thereof |
| AU2001241095A1 (en) | 2000-03-13 | 2001-09-24 | Hisamitsu Pharmaceutical Co. Inc. | Preventives and/or remedies for hyperphosphatemia |
| JP2002028737A (ja) | 2000-07-07 | 2002-01-29 | Fujitsu Ltd | プレス打ち抜き加工方法及びプレス打ち抜き加工装置 |
| NZ528829A (en) * | 2001-04-18 | 2006-06-30 | Genzyme Corp | Low salt forms of polyallylamine |
| JP2004528332A (ja) | 2001-04-18 | 2004-09-16 | ジェンザイム コーポレーション | 痛風を治療する方法および尿酸を結合する方法 |
| AU2003214112A1 (en) | 2002-03-11 | 2003-09-22 | Novartis Ag | Salts of nateglinide |
| EP1597276A4 (en) | 2003-02-10 | 2006-11-29 | Autogen Res Pty Ltd | THERAPEUTIC MOLECULES |
| TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| CN1540136A (zh) * | 2003-10-27 | 2004-10-27 | 华东理工大学 | 一种评价微生物驱油能力的方法 |
| US7767768B2 (en) | 2003-11-03 | 2010-08-03 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7385012B2 (en) | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| US7449605B2 (en) | 2003-11-03 | 2008-11-11 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7459502B2 (en) * | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| US7335795B2 (en) | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7608674B2 (en) * | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
| WO2005065291A2 (en) | 2003-12-31 | 2005-07-21 | Genzyme Corporation | Enteric coated aliphatic amine polymer bile acid sequestrants |
| US20080248012A1 (en) | 2004-01-29 | 2008-10-09 | Keio University | Erythrocyte Function Modifying Substance |
| US8192758B2 (en) | 2004-03-30 | 2012-06-05 | Relypsa, Inc. | Ion binding compositions |
| US7429394B2 (en) | 2004-03-30 | 2008-09-30 | Relypsa, Inc. | Ion binding compositions |
| US7556799B2 (en) | 2004-03-30 | 2009-07-07 | Relypsa, Inc. | Ion binding polymers and uses thereof |
| US7776319B2 (en) | 2004-03-30 | 2010-08-17 | Relypsa, Inc. | Methods and compositions for treatment of ion imbalances |
| US7854924B2 (en) | 2004-03-30 | 2010-12-21 | Relypsa, Inc. | Methods and compositions for treatment of ion imbalances |
| US8282960B2 (en) | 2004-03-30 | 2012-10-09 | Relypsa, Inc. | Ion binding compositions |
| US8399025B2 (en) | 2004-06-04 | 2013-03-19 | Board Of Regents, The University Of Texas System | Polyamine modified particles |
| NZ552706A (en) | 2004-07-19 | 2011-01-28 | Nutricia Nv | Use of aspartate for regulating glucose levels in blood |
| DE102004035808A1 (de) | 2004-07-21 | 2006-03-16 | Kasch, Helmut, Dr. | Ammoniumsalze und Ammoniumsalz-Mineralsalzchlatrate als Transport- und Wirkform für pharmazeutische-medizinische und als Phasentransfermittel für chemische Anwendungen |
| US8569277B2 (en) | 2004-08-11 | 2013-10-29 | Palo Alto Investors | Methods of treating a subject for a condition |
| US20070293429A1 (en) | 2004-10-08 | 2007-12-20 | Therapei Pharmaceuticals, Inc. | Vasoactive Intestinal Polypeptide Compositions |
| US20080214440A1 (en) | 2004-10-08 | 2008-09-04 | Forbes Medi-Tech (Research), Inc. | Vasoactive intestinal polypeptide compositions |
| MX2007004407A (es) * | 2004-10-13 | 2007-07-17 | Ilypsa Inc | Polimeros de amina reticulados. |
| US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
| ITME20040015A1 (it) | 2004-12-07 | 2005-03-07 | Vincenzo Savica | Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico. |
| WO2007004236A2 (en) | 2005-07-04 | 2007-01-11 | Ramu Krishnan | Improved drug or pharmaceutical compounds and a preparation thereof |
| CA3050453C (en) | 2005-08-18 | 2021-07-27 | Panion & Bf Biotech Inc. | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
| JP2009507019A (ja) | 2005-09-02 | 2009-02-19 | ジェンザイム・コーポレーション | リン酸塩を除去する方法およびそれに使用される重合体 |
| GB2446076B (en) | 2005-09-30 | 2010-11-24 | Ilypsa Inc | Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom |
| WO2007038801A2 (en) | 2005-09-30 | 2007-04-05 | Ilypsa, Inc. | Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof |
| KR20080059265A (ko) * | 2005-09-30 | 2008-06-26 | 일립사, 인코포레이티드 | 포유동물의 위장관으로부터 칼륨 이온을 선택적으로제거하기 위한 방법 및 조성물 |
| WO2007055044A1 (ja) | 2005-11-08 | 2007-05-18 | Ajinomoto Co., Inc. | 麻酔覚醒促進剤 |
| WO2007056405A2 (en) | 2005-11-08 | 2007-05-18 | Genzyme Corporation | Magnesium-containing polymers for the treatment of hyperphosphatemia |
| ITMI20052461A1 (it) | 2005-12-22 | 2007-06-23 | Univ Degli Studi Milano | Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive |
| RU2008136081A (ru) | 2006-02-14 | 2010-03-20 | Тева Фармасьютикл Индастриес Лтд. (Il) | Фармацевтические составы с алифатическими аминными полимерами и способы их производства |
| JP2009536246A (ja) | 2006-05-05 | 2009-10-08 | ゲンズイメ コーポレーション | ホスフェート捕捉剤としてのアミン縮合重合体 |
| JP2009542653A (ja) | 2006-07-05 | 2009-12-03 | ジェンザイム コーポレーション | リン酸塩過剰血症のための鉄（ｉｉ）含有治療剤 |
| AU2007275711A1 (en) | 2006-07-18 | 2008-01-24 | Genzyme Corporation | Amine dendrimers |
| CN101541235A (zh) * | 2006-07-18 | 2009-09-23 | 基酶有限公司 | 胺类树状物 |
| US8391873B2 (en) | 2006-07-21 | 2013-03-05 | Qualcomm Incorporated | Systems and methods for coordinating supplementary services for voice telephone calls in a centralized fashion |
| US20090325860A1 (en) | 2006-08-04 | 2009-12-31 | Nastech Pharmaceutical Company Inc. | Compositions for intranasal delivery of human insulin and uses thereof |
| US7964182B2 (en) * | 2006-09-01 | 2011-06-21 | USV, Ltd | Pharmaceutical compositions comprising phosphate-binding polymer |
| BRPI0716066A2 (pt) * | 2006-09-01 | 2013-09-17 | Genzyme Corp | composiÇço farmacÊutica, mÉtodo para tratar doenÇas, polÍmero de amina, rede polimÉrica, mÉtodo para preparar um polÍmero de amina, e, composto de amina |
| WO2008062437A2 (en) | 2006-09-01 | 2008-05-29 | Usv Limited | Process for the preparation of sevelamer hydrochloride and formulation thereof |
| EP2059247A1 (en) | 2006-09-06 | 2009-05-20 | Sucampo AG | Method and composition for promoting gastrointestinal bicarbonate secretion |
| EP2066293A2 (en) | 2006-09-29 | 2009-06-10 | Genzyme Corporation | Amide dendrimer compositions |
| BRPI0720234A2 (pt) | 2006-12-14 | 2013-12-24 | Genzyme Corp | Composição farmacêutica |
| US20100129309A1 (en) | 2007-02-23 | 2010-05-27 | Dhal Pradeep K | Amine polymer compositions |
| US20080207766A1 (en) | 2007-02-27 | 2008-08-28 | Agi Therapeutics Research Ltd. | Methods and compositions for treating at least one upper gastrointestinal symptom |
| WO2008109095A1 (en) | 2007-03-08 | 2008-09-12 | Genzyme Corporation | Sulfone polymer compositions |
| TWI445540B (zh) | 2007-04-20 | 2014-07-21 | Ajinomoto Kk | 抗低體溫組成物 |
| US20100166696A1 (en) | 2007-04-27 | 2010-07-01 | Dhal Pradeep K | Amido-amine dendrimer compositions |
| WO2009005838A2 (en) | 2007-07-02 | 2009-01-08 | Cognate3 Llc | Process for the preparation of a non-corrosive base solution and methods of using same |
| BRPI0813928A2 (pt) * | 2007-07-11 | 2014-12-30 | Toray Industries | Polialilamina reticulada, composição farmacêutica, agente terapêutico ou profilático para hiperfosfatemia, método terapêutico ou profilático para hiperfosfatemia, uso da polialilamina reticulada, e, composto para terapia ou profilaxia de hiperfosfatemia |
| EP2016947A1 (en) | 2007-07-17 | 2009-01-21 | Chemo Ibérica, S.A. | Novel one step process for preparing cross-linked poly(allylamine) polymers |
| WO2009023544A2 (en) | 2007-08-10 | 2009-02-19 | Ilypsa, Inc. | Dosage unit anion-exchange polymer pharmaceutical compositions |
| US20090156647A1 (en) | 2007-12-12 | 2009-06-18 | Iovate T. & P. Inc. | Method for maintaining physiological pH levels during intensive physical exercise |
| WO2009078958A1 (en) | 2007-12-14 | 2009-06-25 | Genzyme Corporation | Coated pharmaceutical compositions |
| PA8807201A1 (es) | 2007-12-14 | 2009-07-23 | Genzyme Corp | Composiciones farmaceuticas |
| WO2009097127A1 (en) | 2008-01-31 | 2009-08-06 | Genzyme Corporation | Pharmaceutical compositions |
| AU2009223063A1 (en) | 2008-03-11 | 2009-09-17 | Livionex Inc. | Methods and compositions for treating inflammation and inflammation-related pathologies |
| US20100331516A1 (en) | 2008-04-08 | 2010-12-30 | Govind Dhananjay Sathe | Process for Preparation of Sevelamer Carbonate |
| BRPI0822017A2 (pt) | 2008-04-11 | 2015-07-21 | Gp Investimenti S R L | Manopla para tratamento de ultrassom em tecido humano. |
| US20110142952A1 (en) | 2008-06-20 | 2011-06-16 | Harris David J | Pharmaceutical Compositions |
| DE102008030046A1 (de) | 2008-06-25 | 2009-12-31 | Ratiopharm Gmbh | Kompaktiertes Polyallylamin-Polymer |
| US20100008988A1 (en) | 2008-07-14 | 2010-01-14 | Glenmark Generics, Ltd. | Tablet compositions of amine polymers |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| US8337824B2 (en) | 2008-08-22 | 2012-12-25 | Relypsa, Inc. | Linear polyol stabilized polyfluoroacrylate compositions |
| WO2010022381A1 (en) | 2008-08-22 | 2010-02-25 | Relypsa, Inc. | Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
| CN105309424B (zh) | 2008-09-25 | 2022-09-02 | 维乌作物保护有限公司 | 生产聚合物纳米颗粒的方法和活性成分的制剂 |
| US20110268666A1 (en) | 2008-09-29 | 2011-11-03 | Yissum Research Development Company of the Research University of Jerusalem, Ltd. | Novel gastroretentive delivery system |
| WO2010059384A1 (en) | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
| US20100166861A1 (en) | 2008-12-29 | 2010-07-01 | Kelly Noel Lynch | Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone |
| KR20110119714A (ko) | 2009-01-22 | 2011-11-02 | 유에스브이 리미티드 | 포스페이트 결합 폴리머를 포함하는 약학적 조성물 |
| CA2777682C (en) | 2009-10-13 | 2015-02-24 | The Regents Of The University Of Michigan | Dendrimer compositions and methods of synthesis |
| US20120219626A1 (en) | 2009-10-22 | 2012-08-30 | Niels Jaap Osinga | Pharmaceutical Compositions of Sevelamer |
| US8735360B2 (en) | 2009-12-07 | 2014-05-27 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| WO2011106542A2 (en) | 2010-02-24 | 2011-09-01 | Relypsa, Inc. | Crosslinked polyvrnylamine, poly all ylamine, and polyethyleneimine for use as bile acid sequestrants |
| EP2538947B1 (en) | 2010-02-24 | 2016-08-17 | Relypsa, Inc. | Polyimidazoles for use as bile acid sequestrants |
| RU2417782C1 (ru) * | 2010-03-03 | 2011-05-10 | Федеральное государственное образовательное учреждение высшего профессионального образования "Белгородская государственная сельскохозяйственная академия" | Способ лечения ацидоза рубца |
| IT1406068B1 (it) | 2010-07-22 | 2014-02-06 | Medestea Int Spa | Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| KR101238210B1 (ko) | 2011-06-30 | 2013-03-04 | 엘지전자 주식회사 | 이동 단말기 |
| US20130137772A1 (en) | 2011-11-29 | 2013-05-30 | Raymond J. Bergeron | Hydroxypolyamine salts |
| JP2015535209A (ja) | 2012-06-21 | 2015-12-10 | ケリク バイオファーマシューティカルス， インコーポレーテッド | 慢性腎臓病患者の治療におけるクエン酸第二鉄の使用 |
| WO2014058905A2 (en) | 2012-10-08 | 2014-04-17 | Relypsa, Inc. | Potassium-binding agents for treating hypertension and hyperkalemia |
| WO2014197725A1 (en) * | 2013-06-05 | 2014-12-11 | Tricida, Inc. | Proton-binding polymers for oral administration |
| SG11201603091QA (en) | 2013-11-04 | 2016-05-30 | Keryx Biopharmaceuticals Inc | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
| MA41150B1 (fr) | 2014-12-10 | 2020-06-30 | Tricida Inc | Polymères de liaison aux protons pour administration orale |
| MA44875A (fr) | 2016-05-06 | 2019-03-13 | Tricida Inc | Compositions pour le traitement de troubles acido-basiques |
| AU2018360867A1 (en) | 2017-11-03 | 2020-04-30 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
| WO2019090177A1 (en) | 2017-11-03 | 2019-05-09 | Tricida, Inc. | Method of treating acid-base disorders |
| WO2019236124A1 (en) | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| WO2019236639A1 (en) | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| MA51628A (fr) | 2018-06-04 | 2021-03-17 | Tricida Inc | Méthode de traitement de troubles de l'équilibre acido-basique |
-
2014
- 2014-06-05 WO PCT/US2014/041152 patent/WO2014197725A1/en active Application Filing
- 2014-06-05 DK DK17177221.3T patent/DK3287133T3/da active
- 2014-06-05 HU HUE14742001A patent/HUE034836T2/en unknown
- 2014-06-05 KR KR1020217034420A patent/KR20210131457A/ko not_active Application Discontinuation
- 2014-06-05 PT PT17177221T patent/PT3287133T/pt unknown
- 2014-06-05 KR KR1020157036999A patent/KR102318910B1/ko active IP Right Grant
- 2014-06-05 ES ES14742001.2T patent/ES2646271T3/es active Active
- 2014-06-05 KR KR1020237024806A patent/KR102633597B1/ko active IP Right Grant
- 2014-06-05 HU HUE19169259A patent/HUE051198T2/hu unknown
- 2014-06-05 DK DK14742001.2T patent/DK3003327T3/en active
- 2014-06-05 DK DK19169259.9T patent/DK3578185T3/da active
- 2014-06-05 PL PL14742001T patent/PL3003327T3/pl unknown
- 2014-06-05 HU HUE17177221A patent/HUE043999T2/hu unknown
- 2014-06-05 PL PL17177221T patent/PL3287133T3/pl unknown
- 2014-06-05 JP JP2016518006A patent/JP6453860B2/ja active Active
- 2014-06-05 SI SI201431698T patent/SI3578185T1/sl unknown
- 2014-06-05 RS RS20201307A patent/RS61005B1/sr unknown
- 2014-06-05 KR KR1020247003745A patent/KR20240023672A/ko active Search and Examination
- 2014-06-05 CN CN201480032395.1A patent/CN105377270B/zh active Active
- 2014-06-05 BR BR112015030142-8A patent/BR112015030142B1/pt active IP Right Grant
- 2014-06-05 EP EP14742001.2A patent/EP3003327B1/en active Active
- 2014-06-05 SI SI201430466T patent/SI3003327T1/en unknown
- 2014-06-05 PT PT191692599T patent/PT3578185T/pt unknown
- 2014-06-05 ES ES17177221T patent/ES2733493T3/es active Active
- 2014-06-05 CN CN202010780603.3A patent/CN111671766B/zh active Active
- 2014-06-05 SI SI201431241T patent/SI3287133T1/sl unknown
- 2014-06-05 TR TR2019/09355T patent/TR201909355T4/tr unknown
- 2014-06-05 LT LTEP19169259.9T patent/LT3578185T/lt unknown
- 2014-06-05 CN CN202010780604.8A patent/CN111671767B/zh active Active
- 2014-06-05 RS RS20190806A patent/RS59033B1/sr unknown
- 2014-06-05 EP EP20183421.5A patent/EP3812761A1/en active Pending
- 2014-06-05 MX MX2015016527A patent/MX364785B/es active IP Right Grant
- 2014-06-05 PT PT147420012T patent/PT3003327T/pt unknown
- 2014-06-05 LT LTEP17177221.3T patent/LT3287133T/lt unknown
- 2014-06-05 LT LTEP14742001.2T patent/LT3003327T/lt unknown
- 2014-06-05 CA CA2912911A patent/CA2912911C/en active Active
- 2014-06-05 EP EP17177221.3A patent/EP3287133B1/en active Active
- 2014-06-05 EP EP19169259.9A patent/EP3578185B1/en active Active
- 2014-06-05 AU AU2014274817A patent/AU2014274817B2/en active Active
- 2014-06-05 ES ES19169259T patent/ES2834485T3/es active Active
- 2014-06-05 RU RU2015155596A patent/RU2728778C2/ru active
- 2014-06-23 US US14/311,852 patent/US9205107B2/en active Active
-
2015
- 2015-01-27 NO NO15000230A patent/NO2905572T3/no unknown
- 2015-11-18 US US14/944,844 patent/US9925214B2/en active Active
- 2015-11-24 IL IL242758A patent/IL242758B/en active IP Right Grant
- 2015-12-01 MX MX2021013880A patent/MX2021013880A/es unknown
- 2015-12-01 MX MX2019005300A patent/MX2019005300A/es unknown
-
2016
- 2016-08-30 HK HK16110308.8A patent/HK1222120A1/zh unknown
- 2016-10-05 HK HK16111588.7A patent/HK1223288A1/zh unknown
-
2017
- 2017-09-26 US US15/715,934 patent/US9993500B2/en active Active
- 2017-10-18 HR HRP20171590TT patent/HRP20171590T1/hr unknown
- 2017-11-06 CY CY20171101159T patent/CY1119611T1/el unknown
-
2018
- 2018-06-07 US US16/002,269 patent/US10363268B2/en active Active
- 2018-06-07 US US16/002,306 patent/US10391118B2/en active Active
- 2018-08-16 HK HK18110550.1A patent/HK1251151B/zh unknown
- 2018-12-13 JP JP2018233254A patent/JP6759316B2/ja active Active
-
2019
- 2019-04-04 US US16/375,843 patent/US10369169B1/en active Active
- 2019-06-14 HR HRP20191074TT patent/HRP20191074T1/hr unknown
- 2019-07-04 CY CY20191100694T patent/CY1121801T1/el unknown
- 2019-08-16 US US16/542,969 patent/US11197887B2/en active Active
- 2019-08-22 AU AU2019219800A patent/AU2019219800B1/en active Active
- 2019-12-04 AU AU2019275584A patent/AU2019275584B2/en active Active
-
2020
- 2020-01-09 IL IL271932A patent/IL271932B/en active IP Right Grant
- 2020-09-02 JP JP2020147224A patent/JP7075455B2/ja active Active
- 2020-10-20 IL IL278183A patent/IL278183B/en unknown
- 2020-10-30 CY CY20201101028T patent/CY1123673T1/el unknown
- 2020-11-02 HR HRP20201767TT patent/HRP20201767T1/hr unknown
-
2021
- 2021-12-09 US US17/546,339 patent/US20220096534A1/en active Pending
-
2022
- 2022-05-13 JP JP2022079329A patent/JP2022107004A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191074T1 (hr) | Polimeri koji vežu protone za oralnu primjenu | |
| JP2016520652A5 (hr) | ||
| ATE424437T1 (de) | Biozide beschichtungen | |
| AU2021245144B2 (en) | Proton-binding polymers for oral administration | |
| JP2017516884A5 (hr) | ||
| JP2016508144A5 (hr) | ||
| JP2016500897A5 (hr) | ||
| JP2013057058A5 (ja) | ブロック共重合体の塗膜 | |
| AR103697A1 (es) | Composiciones con efecto inhibidor de la ureasa mejorado que comprenden triamida del ácido (tio)fosfórico y otros compuestos, tales como aminas y colorantes | |
| JP2015530462A5 (hr) | ||
| JP2014515406A5 (hr) | ||
| BR112020002147A2 (pt) | composição e método para melhorar a estabilidade de composições de espuma aquosas e resistentes ao álcool | |
| JP2014528836A5 (hr) | ||
| CA2620406A1 (en) | Method for removing phosphate and polymer used therefore | |
| JPWO2015045883A1 (ja) | （メタ）アクリル酸系共重合体とその製造方法 | |
| JP2009143975A (ja) | 固体電解質用材料 | |
| AR060751A1 (es) | Polimeros de condensacion de aminas como secuestrantes de fosfatos | |
| CN106719681B (zh) | 一种油田杀菌缓蚀剂及其制备方法 | |
| Taden et al. | Synthesis and polymerization of 5‐(methacrylamido) tetrazole, a water‐soluble acidic monomer | |
| GB1302167A (hr) | ||
| JP7474340B2 (ja) | 表面処理液、及び表面処理方法 | |
| JP2007335119A (ja) | 固体電解質用材料 | |
| JP6662541B2 (ja) | 疎水性基含有共重合体及び分散剤 | |
| JP2020069414A (ja) | 二酸化炭素の分離組成物 | |
| JP2014070108A (ja) | キレート剤含有組成物 |